To determine whether the correlation between BCR diversity and survival is BCC-specific or represents a more generalizable phenomenon following checkpoint blockade, we aggregated data from published studies that include pre- and postimmunotherapy tumor sequencing and clinical outcomes. This evidence concerns the gene BCR and skin basal cell carcinoma.